
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences anticipates robust revenue growth, projecting total sales of $5.83 billion by 2025, representing a 9.2% year-over-year increase, bolstered by a $4.27 billion revenue estimate from its transcatheter aortic valve replacement (TAVR) segment, which is expected to grow at 6.4% year-over-year. The company has demonstrated strong performance in its transcatheter mitral and tricuspid technologies, with exceptional TMTT growth of 85% year-over-year, reflecting significant market demand and positioning. Additionally, Edwards Lifesciences' global sales strength, with approximately 60% of total sales derived from international markets, further underscores its expansive growth potential in the evolving cardiovascular device landscape.
Bears say
Edwards Lifesciences anticipates that both total company and transcatheter aortic valve replacement (TAVR) growth rates for Q1 2025 will fall below the lower bounds of their previously established full-year guidance ranges, largely due to the impact of one less selling day. Additionally, potential revenue growth headwinds are identified, including macroeconomic factors, slower market uptake for TAVR, challenges in penetrating the transcatheter mitral valve replacement (TMVR) market, and increasing competition. Furthermore, the impact of foreign exchange fluctuations is projected to present a significant headwind, estimated at approximately $130 million, which could negatively affect overall sales performance.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares